INXN-4001 is a non-viral, multigene plasmid designed to express three different human proteins. A unique triple-effector plasmid, INXN-4001 addresses multiple malfunctions of cardiomyocytes in patients with heart failure.
INXN-4001 is being studied clinically to assess its safety and feasibility of minimally invasive retrograde coronary sinus infusion (RCSI) in left ventricular assist device (LVAD) patients.
This first INXN-4001 clinical study is designed to evaluate the safety of INXN-4001 in LVAD patients as assessed by the incidence rate of all adverse events occurring up to six months post-treatment.
The study will also examine the ability of LVAD patients to wean from the LVAD device, their quality of life, and their overall daily activity.
INXN-4001 represents the leading program in Precigen's majority-owned subsidiary Xogenex, LLC, a company focused on the development of multi-genic biological therapies for cardiovascular disease.
Precigen is advancing the next generation of gene and cellular therapies using precision technology to target the most urgent and intractable diseases in oncology, autoimmune disorders, and emerging specialty therapy areas.
The company operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-confidence and commercialisation.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886